Source: Eur Respir J 2014; 44: 23-63
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Lange Christoph, Abubakar Ibrahim, Alffenaar Jan-Willem C., Bothamley Graham, Caminero Jose A., Carvalho Anna Cristina C., Chang Kwok-Chiu, Codecasa Luigi, Correia Ana, Crudu Valeriu, Davies Peter, Dedicoat Martin, Drobniewski Francis, Duarte Raquel, Ehlers Cordula, Erkens Connie, Goletti Delia, Günther Gunar, Ibraim Elmira, Kampmann Beate, Kuksa Liga, de Lange Wiel, van Leth Frank, van Lunzen Jan, Matteelli Alberto, Menzies Dick, Monedero Ignacio, Richter Elvira, Rüsch-Gerdes Sabine, Sandgren Andreas, Scardigli Anna, Skrahina Alena, Tortoli Enrico, Volchenkov Grigory, Wagner Dirk, van der Werf Marieke J., Williams Bhanu, Yew Wing-Wai, Zellweger Jean-Pierre, Cirillo Daniela Maria. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 2014; 44: 23-63

Member's Comments

No comment yet.

Related content which might interest you: Facilities for treating multidrug-resistant tuberculosis (MDRTB) in Europe Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016 MDR-TB guidelines: what is new on clinical management Source: ERS Webinar 2020: MDR-TB guidelines: what is new on clinical management Year: 2020 Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 National advisory services for multidrug-resistant tuberculosis (MDRTB) in Europe: an ERS-TBnet survey Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Treatment results in patients with XDR tuberculosis in Ukraine Source: Eur Respir J 2007; 30: Suppl. 51, 272s Year: 2007 Genotypes and drug resistance patterns of multi-drug-resistant mycobacterium tuberculosis strains in Pakistan Source: International Congress 2015 – Non-tuberculous mycobacteria and molecular microbiology Year: 2015 HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014 The risk of default in TB patients in the Russian Federation Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 2 Year: 2014 Transmission of mycobacterium tuberculosis Ural 163-15 lineage causing multidrug-resistant tuberculosis among hospitalized patients Source: International Congress 2015 – Management of TB: a patient focus Year: 2015 Four cases, one family: A cluster of resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Minimum package for cross-border TB control and care in the WHO European region: a Wolfheze consensus statement Source: Eur Respir J 2012; 40: 1081-1090 Year: 2012 Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Features of different M.tuberculosis strains that were isolated from MDR-TB patients in Kharkiv, Ukraine Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016 Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015 Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012